DC Chemicals Limited
China
Product Name: 4-IPP (4-Iodo-6-phenylpyrimidine)
Price: $650.0/100mg $1100.0/250mg $2100.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

41270-96-6

41270-96-6 structure

41270-96-6 structure

Name: 4-IPP
Chemical Name: 4-Iodo-6-phenylpyrimidine
CAS Number: 41270-96-6
Molecular Formula: C₁₀H₇IN₂
Molecular Weight: 282.08000
Catalog: Research Areas Metabolic Disease
Create Date: 2017-09-01 01:09:03
Modify Date: 2024-01-13 12:51:23
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].

Name	4-Iodo-6-phenylpyrimidine
Synonyms	4-Jod-2-methyl-6-nitro-anilin iodomethylnitroaniline 4-iodo-2-methyl-6-nitro-aniline 4-iodo-6-phenyl-pyrimidine 4-iodo-2-methyl-6-nitrobenzenamine 4-iodo-6-methyl-2-nitroaniline 5-Jod-3-nitro-2-amino-toluol

Description	4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
Target	MIF[1]
In Vitro	4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1]. 4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1]. 4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1]. 4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1]. 4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1]. Cell Cytotoxicity Assay[1] Cell Line: BMMs Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM Incubation Time: 24 hours, 72 hours Result: Inhibited osteoclastogenesis in a dose-dependent manner. Western Blot Analysis[1] Cell Line: BMMs Concentration: 5 μM,10 μM, 20 μM Incubation Time: 1 day, 3 days, 5 days Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption.
In Vivo	4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1]. Animal Model: 8-weeks-old C57BL/6J male mice[1] Dosage: 1 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; every 2 days; for 8 weeks Result: Alleviated OVX-induced osteoporosis.
References	[1]. Zheng L, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. FASEB J. 2019 Jun;33(6):7667-7683.

Density	1.728±0.06 g/cm3
Boiling Point	380.2±30.0 °C
Molecular Formula	C₁₀H₇IN₂
Molecular Weight	282.08000
Exact Mass	281.96500
PSA	25.78000
LogP	2.74820
Storage condition	-20°C

Symbol	GHS05, GHS07
Signal Word	Danger
Hazard Statements	H302-H315-H318-H335
Precautionary Statements	P261-P280-P305 + P351 + P338
Hazard Codes	C
RIDADR	NONH for all modes of transport